Back to results
US 11,304,907 B2Granted
Pharmaceutical compositions containing a DGAT1 inhibitor
AssigneeNovartis AG
InventorsHong Wen, Natrajan Kumaraperumal, Richard Nause
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition comprising a) a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, b) one or more, e.g. 1, 2 or 3, surfactants with lubricant properties; c) one or more, e.g. 1, 2 or 3, dry binders with disintegrant properties; d) one or more, e.g. 1, 2 or 3, fillers, and e) one or more, e.g. 1, 2 or 3, disintegrants.
Claims13
A pharmaceutical composition in the form of a tablet comprising
- a) a therapeutically effective amount of the sodium salt of the compound trans-(4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid of formula (I);
- b) 2% of sodium lauryl sulfate by weight of the tablet prior to any optional film coating;
- c) 10% of hydroxypropyl cellulose by weight of the tablet prior to any optional film coating;
- d) 15 to 26% of microcrystalline cellulose by weight of the tablet prior to any optional film coating;
- e) 0.5% of colloidal silica by weight of the tablet prior to any optional film coating;
- f) 3% of sodium stearyl fumarate by weight of the tablet prior to any optional film coating;
- g) 20 to 85% of anhydrous lactose by weight of the tablet prior to any optional film coating;
- h) 2% of sodium starch glycolate by weight of the tablet prior to any optional film coating;
- and
- i) an optional film coating.
7 more elements
Dependencies are inferred from the claim text.